Scotiabank analyst Louise Chen has reiterated a 'Sector Outperform' rating for Amgen and increased its price target from $385 to $450. This indicates a positive outlook from the analyst, suggesting potential upside for Amgen's stock.
Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Amgen and raised the price target from $385 to $450. This action signals increased confidence from the analyst in Amgen's future performance and valuation. For traders, this presents a short-term opportunity as the raised price target could attract more buying interest, potentially driving the stock price up. Long-term implications depend on Amgen's actual financial performance and pipeline developments, but the analyst's positive stance provides a favorable backdrop. The key opportunity for traders is to capitalize on the potential upward momentum following this positive analyst revision.